Latest features in GaBI Journal, 2012, issue 3-4
A bioethicist’s view of the use of biosimilars
A clinician’s view of the ethics of the use of biosimilars
Generics policies–a globally-relevant implementation challenge
Reference price systems: stakeholder dialogue and involvement
Statin generics: no differences in efficacy after switching
Pharmacovigilance of biosimilars: challenges and possible solutions
Saving money in the European healthcare systems with biosimilars
Reference pricing systems in Europe: characteristics and consequences
Terminology for biosimilars–a confusing minefield
Health professionals in the risk communication process on counterfeit medicines
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes
The potential of generics policies: more room for exploitation–PPRI Conference Report
Austria could save Euros 256 million by using more generics
The potential for doctors to contribute to biosimilar guidelines
Source URL: https://gabi-journal.net/20123-4-gabi-journal-table-of-contents.html
Copyright ©2024 GaBI Journal unless otherwise noted.